ArticleNuclear medicine communications2025
Associations between brown adipose tissue activity, serum lipid profiles, and cardiovascular events: insights from 18 F-fluorodeoxyglucose PET/computed tomography analysis.
Article in Nuclear medicine communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Functional Complexity of Thermogenic Adipose Tissue: From Thermogenesis to Metabolic and Fibroinflammatory Crosstalk.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveThis study investigated the associations between brown adipose tissue (BAT) metabolic parameters, serum lipid profiles, and cardiovascular disease (CVD) events.
methodsA retrospective cohort study involving 13 530 patients who underwent 18 F-fluorodeoxyglucose ( 18 F-FDG) PET/computed tomography between November 2019 and March 2024 was conducted to evaluate semiquantitative BAT indices, including the maximum standardized uptake value (B-SUV max ), total metabolic volume (TBMV), and total BAT glycolytic activity (TBG), as well as their associations to lipid profiles [total cholesterol (TC), triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and TC/HDL-C and LDL-C/HDL-C ratios) and CVD outcomes. Propensity score matching was applied, resulting in a comparison group of 74 BAT-positive patients and 148 BAT-negative controls.
resultsBAT-positive individuals exhibited significantly higher HDL-C levels ( P = 0.005) and lower TC/HDL-C ( P = 0.006) and LDL-C/HDL-C ( P = 0.014) ratios compared with controls, while no significant differences were observed in triglyceride, TC, or LDL-C levels. TBG showed the strongest correlations with HDL-C ( r = 0.256, P < 0.001), TC/HDL-C ( r = -0.223, P < 0.001), and LDL-C/HDL-C ( r = -0.195, P = 0.004), outperforming B-SUV max and TBMV. Patients exhibiting BAT had a lower incidence of CVD events compared to those without detectable BAT ( P = 0.018). Multivariate logistic regression analysis showed that the presence of BAT is an independent predictor of CVD events.
conclusionTBG is a moderate biomarker reflecting HDL-C levels and the ratios of TC/HDL-C and LDL-C/HDL-C, while detectable BAT activity independently correlates with reduced CVD risk, highlighting its potential for cardiovascular risk stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.